Trial · NCT07360938
Drug Interaction Potential of Pro-Inflammatory Conditions
Pro-inflammatory cytokines, which are elevated in pro-inflammatory disease states (e.g., type II diabetes mellitus \[T2DM\], irritable bowel diseases \[IBD\], a
- Status
- Recruiting
- Sponsor
- Indiana University
- Study type
- Observational
- Phase
- Not applicable
- Enrollment
- 150 participants (planned)
- Start
- Nov 1, 2025
- Primary completion
- Dec 31, 2028
- Conditions
- Diabetes Mellitus, Type 2, End Stage Renal Disease, Irritable Bowel Syndrome
Summary
Pro-inflammatory cytokines, which are elevated in pro-inflammatory disease states (e.g., type II diabetes mellitus \[T2DM\], irritable bowel diseases \[IBD\], and end stage renal disease \[ESRD\]) have been shown to inhibit hepatic drug-metabolizing enzymes, including members of the cytochrome P450 (CYP) family, and drug transporters; resultantly, pro-inflammatory diseases have been demonstrated to increase the exposure and potential for adverse drug events with co-administered CYP and drug transporter substrates.
Interventions
- None (Observational) Other
Locations
1 country: United States.
| Facility | City | Country |
|---|---|---|
| Indiana University Hospital | Indianapolis, Indiana | United States |
TreatIBS is an informational site and does not provide medical advice. The research summarized here may not apply to your situation. Talk with a clinician before starting, stopping, or changing any treatment.
Listing only. Eligibility is decided by the study team. TreatIBS is not involved in recruitment.